New Jersey, USA-based Merck & Co (NYSE: MRK) has announced strong third quarter 2018 financial results, with global revenues up 5% on the same period last year, at $10.8 billion, in line with analysts’ expectations.
The firm said it would boost its dividend by 15% and spend $10 billion repurchasing shares.
Following Generally Accepted Accounting Principles (GAAP), net income was $1.95 billion, or $0.73 per share, compared with a loss of $56 million in 2017.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze